Recent client announcements are drawing fresh attention to DuPont de Nemours (DD) as its Tyvek cleanroom garments gain expanded availability through Flow Cleanrooms & Supply, and its MemCor membrane bioreactor technology is selected for a major Australian wastewater upgrade.
See our latest analysis for DuPont de Nemours.
These contract wins arrive after a mixed spell for DuPont de Nemours, with the share price at $138.33, a year to date share price return of 12.82%, but a 1 year total shareholder return of 45.22% that points to stronger longer term momentum.
If these developments have you thinking about where else growth stories may be emerging, it could be worth scanning other industrial and infrastructure players through the 39 power grid technology and infrastructure stocks
Bulls point to DuPont de Nemours’ cleanroom and water contracts, along with a 45.22% 1-year return. Bears focus on recent share price softness and cyclicality. Which side does the current valuation evidence support?
Most Popular Narrative: 19.6% Undervalued
Compared to the last close at $138.33, the most followed narrative for DuPont de Nemours points to a materially higher fair value anchored at $172.07, built on detailed forecasts for revenue, margins and future earnings multiples.
Persistent strength and strategic investment in Healthcare & Water, driven by surging global demand for clean water solutions and healthcare products, leverages favorable demographic, sustainability, and infrastructure trends to drive above-peer organic revenue growth and margin stability. The company's renewed portfolio focus post Qnity spin and recent divestitures in non core segments enables greater resource allocation to high growth specialty businesses, contributing to improved operating margin and increased earnings stability.
Want to see how this fair value gets built from the ground up? The narrative leans heavily on revenue compounding, margin rebuild, and a re-rated earnings multiple. Curious which of those drivers does most of the heavy lifting in the model.
Result: Fair Value of $172.07 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors in DuPont de Nemours still need to weigh ongoing PFAS legal exposures and the risk that portfolio changes could leave the business less diversified and more volatile.
Find out about the key risks to this DuPont de Nemours narrative.
Another View on DuPont de Nemours Valuation
The analyst narrative suggests DuPont de Nemours looks undervalued relative to a fair value of $172.07. However, the current P/E of 61x is far above the Industrials industry average of 11.5x, a peer average of 29.1x, and a fair ratio of 40.9x. That gap points to meaningful valuation risk if sentiment shifts.
Investors who rely more on simple earnings multiples than on detailed narratives may want to see how these numbers line up in a fuller breakdown before reaching a conclusion about DuPont de Nemours. See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed sentiment around DuPont de Nemours, it makes sense to move quickly and review the data yourself before opinions harden. To see both the potential upsides and the areas investors are worried about, take a closer look at the 4 key rewards and 2 important warning signs.
Looking for more investment ideas beyond DuPont de Nemours?
If DuPont de Nemours has sharpened your appetite for ideas, do not stop here. The next move could sit in a very different corner of the market.
- Target potential mispricing opportunities by scanning companies that combine quality fundamentals with attractive valuations through the 48 high quality undervalued stocks.
- Build a steadier income stream by focusing on companies with robust payouts using the 12 dividend fortresses.
- Dial back portfolio risk by filtering for companies with stronger financial resilience via the 75 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com